Microdosing Protocols: Fadiman, Stamets Stack, and Beyond

Microdosing Protocols: Fadiman, Stamets Stack, and Beyond

Microdosing — the practice of taking sub-perceptual doses of psilocybin on a scheduled basis — has become one of the most widely discussed and practiced psychedelic applications. Unlike full-dose therapeutic sessions, microdosing involves amounts small enough that they produce no significant alteration of consciousness, yet users report effects on mood, cognitive function, creativity, and emotional regulation.

The available protocols vary significantly in dosing schedule, dose size, and whether additional compounds are combined. Understanding the differences — and the evidence (and lack thereof) behind each approach — allows for more informed decision-making about which protocol to try and how to track outcomes.

What Counts as a Microdose?

A microdose is generally defined as 1/10 to 1/20 of a standard recreational or therapeutic dose. For Psilocybe cubensis:

• Standard full dose: 3–3.5g dried mushrooms (or ~25mg synthetic psilocybin)
• Microdose range: 0.05–0.3g dried mushrooms
• Most commonly reported effective range: 0.1–0.2g

At proper microdose levels:

• No visual effects or perceptual alteration
• No impairment of driving, work, or social function
• No significant mood alteration on dose day specifically
• Effects (if present) are often subtle: slightly sharper focus, slightly less emotional reactivity

If you can tell with certainty that you've taken something, the dose may be in "mini-dose" territory (0.3–0.8g) — which has different characteristics than true microdosing.

The Fadiman Protocol

Developed by psychologist James Fadiman based on citizen science data collected over several years, the Fadiman protocol is the most widely known and studied microdosing schedule.

Schedule: 1 day on, 2 days off

• Day 1: Dose
• Day 2: No dose (Fadiman calls this the "transition day" — when residual effects may be felt)
• Day 3: No dose (the "normal day" — baseline comparison)
• Day 4: Dose again

Typical dose: 0.1–0.2g dried Psilocybe cubensis (or equivalent synthetic psilocybin)

Duration: Fadiman's original protocol suggests 4–8 weeks, then a break of equal duration before assessing whether to continue.

Rationale: The 2-day off days prevent tolerance buildup (psilocybin produces rapid tolerance via 5-HT2A receptor downregulation — daily use would make it ineffective within days). The alternating structure also allows clear comparison between dose days and off days.

What the data shows: The Fadiman citizen science dataset (thousands of self-report entries) is the largest microdosing dataset collected under a systematic protocol. Reported benefits cluster around mood, focus, emotional regulation, and creativity. Significant limitations: no control condition, strong expectancy effects, self-selected sample.

Best suited for: First-time micrododosers who want a well-documented, simple protocol. People who want comparison data on dose vs. non-dose days.

The Stamets Stack

Developed by mycologist Paul Stamets, the Stamets stack combines psilocybin microdosing with two non-psychoactive supplements: lion's mane mushroom extract (Hericium erinaceus) and niacin (vitamin B3).

Schedule: 5 days on, 2 days off

• Days 1–5: Dose (psilocybin + lion's mane + niacin)
• Days 6–7: Rest

Typical doses:

• Psilocybin: 0.1–0.2g dried mushrooms (or ~1–2mg synthetic)
• Lion's mane: 50–200mg extract (standardized for erinacines/hericenones)
• Niacin: 100–200mg (not niacinamide — niacin that produces the flush)

Stamets' rationale:

• Psilocybin + lion's mane: Stamets proposes a synergistic neurogenesis effect — psilocybin promotes neuroplasticity via 5-HT2A and BDNF; lion's mane promotes Nerve Growth Factor (NGF). Together, they may produce more robust neurological regeneration.
• Niacin: Stamets proposes that the "niacin flush" (peripheral vasodilation, tingling sensation) acts as a delivery mechanism, driving the other compounds into peripheral neurological tissue.

What the data shows: The synergy hypothesis is plausible but unproven in humans. Lion's mane has independent evidence for NGF promotion and some cognitive benefit (small human trials for mild cognitive impairment). The niacin delivery mechanism is speculative. No human trial has tested the Stamets stack combination as designed.

Side effects and cautions:

• Niacin flush (facial flushing, tingling, itching) is uncomfortable for some users, particularly at higher doses; starting at 50mg and titrating up is advisable
• Lion's mane has excellent safety profile; rare allergy reports
• Niacin at higher doses (>500mg) can affect liver enzymes and lipid metabolism; the doses in the Stamets stack (100–200mg) are generally considered safe for most people

Best suited for: People specifically interested in neurogenesis and cognitive enhancement applications; people interested in the lion's mane-psilocybin synergy hypothesis; people who tolerate niacin flush.

The Nightcap Protocol

A variation that schedules microdoses in the evening to minimize any subtle psychoactive effects during daytime functioning.

Schedule: Typically Fadiman-pattern (every 3rd day) but timed in the evening

Rationale: Some users find that even sub-perceptual doses produce subtle stimulation that can interfere with sleep if taken too late, or subtle mental agitation that affects work if taken in the morning. Evening dosing separates any dose-day effects from work/daytime functioning.

What changes: The "dose day" effects occur during sleep rather than waking hours. Some users report more vivid dreams on dose nights. Morning of the day after dosing is often reported as the period of clearest cognitive effects.

Best suited for: People who find daytime doses interfere with work even at low amounts; people sensitive to stimulation effects.

The Intuitive / Variable Protocol

Some experienced micrododosers move away from fixed schedules toward more intuitive dosing — taking a microdose when it feels called for, with off days based on internal cues rather than a fixed schedule.

Characteristics: Less systematic; requires experience to assess dose-day effects accurately; risk of insufficient gap days and tolerance development.

Best suited for: Experienced micrododosers who have established their individual response through structured protocols and want more flexibility.

Tracking Outcomes

Regardless of which protocol you use, outcome tracking is essential for determining whether microdosing is producing actual effects versus expectancy.

What to track daily:

• Mood (1-10 scale, time of day specified)
• Energy (1-10)
• Focus and cognitive performance (1-10)
• Emotional reactivity or anxiety (1-10)
• Sleep quality (1-10)
• Any noteworthy events or observations

Tracking methods: Paper journal, spreadsheet, dedicated apps (MicroTrack, journal templates from citizen science projects).

The blinding problem: Expectancy effects are a demonstrated significant confounder in microdosing research. The Szigeti et al. self-blinding study (Imperial College London, 2021) — the most rigorous microdosing research design — showed that expectancy accounted for a substantial portion of self-reported benefits. To address this:

• Use the Szigeti self-blinding protocol if rigorous assessment is important (prepare some capsules as placebos without knowing which is which)
• At minimum, be aware that expectancy will inflate perceived benefit on dose days

When to stop: If you're not observing measurable differences between dose and off days after 4 weeks, the protocol may not be producing effects for you. If you observe significant anxiety, emotional instability, or sleep disruption, reduce dose or stop.

Common Microdosing Mistakes

Dosing too frequently: Daily dosing produces rapid tolerance; the experience flattens within days. All effective protocols include consistent off days.

Dosing too high: The "more is more" intuition fails at microdose levels. Doses in the mini-dose range (0.3–0.8g) produce different and often less functional effects than true microdoses.

Not tracking: Without tracking, it's impossible to distinguish actual effects from expectancy and placebo.

Expecting too much: Microdosing is not a substitute for therapy, lifestyle change, or medical treatment. The evidence base for dramatic effects is weak; modest, subtle effects are what most people in rigorous tracking observe.

Combining with alcohol or cannabis: Alcohol works against microdosing benefits by suppressing neuroplasticity; cannabis can amplify psilocybin effects unpredictably at microdose levels, pushing the dose into perceptual territory.

Safety Profile

Psilocybin microdosing has a favorable safety profile in the literature:

• No cardiovascular risk at microdose levels in healthy adults
• No evidence of dependence or addiction
• No documented long-term adverse outcomes in systematic surveys
• Rare reports of increased anxiety in sensitive individuals, particularly at higher microdoses or in combination with caffeine

The main understudied risk: effects in people with personal or family history of psychosis or mania. Even microdoses may theoretically activate these vulnerabilities in susceptible individuals. People with psychosis history, bipolar I, or first-degree relatives with schizophrenia should approach microdosing with significant caution and medical consultation.